A clinical pharmacologist is reviewing medication charts for several patients admitted to the internal medicine service. Various drug-related changes in efficacy, toxicity, and duration of action are noted. Identify the underlying pharmacokinetic or pharmacodynamic mechanism that best explains each patient's clinical presentation.
- An 80-year-old patient exhibits a significantly prolonged duration of action after receiving a standard dose of a highly lipophilic sedative.Increased volume of distribution () secondary to age-related changes in body composition.
- A patient on chronic phenytoin therapy develops acute ataxia and nystagmus following only a 10% increase in their daily maintenance dose.Transition from first-order to zero-order elimination kinetics due to enzyme saturation.
- A patient treated with warfarin develops subtherapeutic international normalized ratio (INR) levels two weeks after initiating therapy with carbamazepine.Increased hepatic clearance secondary to transcriptional upregulation of metabolic enzymes.
- A patient receiving long-term treatment with a full agonist opioid requires progressively larger doses to maintain adequate pain control.Decreased receptor sensitivity or receptor downregulation resulting in pharmacodynamic tolerance.
Cevap
The clinical scenarios map to their respective mechanisms: prolonged sedation in the elderly maps to increased volume of distribution; phenytoin toxicity maps to zero-order kinetics; warfarin failure maps to enzyme induction; and opioid dose escalation maps to pharmacodynamic tolerance.
Each scenario illustrates a fundamental principle of pharmacokinetics or pharmacodynamics. Aging inherently increases body fat percentages, expanding the distribution volume for lipophilic substances and thereby increasing half-life. Phenytoin's saturable metabolism means that once enzymes are working at maximum capacity, any further dose increase cannot be cleared efficiently, leading to rapid toxicity. Carbamazepine transcriptionally upregulates hepatic enzymes, which accelerates the clearance of co-administered drugs like warfarin, rendering them subtherapeutic. Finally, continuous receptor stimulation by opioids causes receptor downregulation, a classic cellular mechanism of pharmacodynamic tolerance.
Adım Adım Çözüm
Anahtar Kavram
Pharmacokinetic and pharmacodynamic principles including alterations in volume of distribution, Michaelis-Menten kinetics, enzyme induction, and pharmacodynamic tolerance.